May 18, 2015 9:21am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK) today announced six important new clinical
trial results pertaining to the 4Kscore® test presented at the 2015
American Urological Association (AUA) annual meeting, May 15 to May 19,
2015, in New Orleans.
Date and time, title and location of the 4Kscore
Friday, May 15, 1:00 pm – Moderated poster MP6-04: The 4Kscore Test
predicts high-grade prostate cancer on biopsy with PSA less than 4
ng/mL; NOMCC #220-221
Sunday May 17, 11:10 am – Urologic Oncology Forum podium presentation:
Screening for lethal prostate cancer using PSA and related blood
biomarkers; NOMCC #356-357
Sunday May 17, 12:50 am – Urologic Oncology Forum podium presentation:
Use of commercial blood biomarkers to identify risk of aggressive
prostate cancer; NOMCC #356-357
Monday, May 18, 8:00 am – Moderated poster MP60-06: The performance of
the 4Kscore for predicting high-grade cancer on biopsy of the prostate
does not depend on the age of the patient; NOMCC #206-207
Monday May 18, 10:30 am – Podium presentation PD38-03: The 4Kscore is
associated with more advanced disease at radical prostatectomy; Results
from a multi-Institutional prospective trial; NOMCC #215-216
Tuesday, May 19, 8:00 am – Moderated poster MP77-20: Among men with
low-grade prostate cancer on prostate biopsy, the 4Kscore predicts more
aggressive prostate cancer at prostatectomy; NOMCC 228-230
In addition to the regular AUA program presentations, the OPKO 4Kscore
test will also be featured on Tuesday May 19 th in an industry
Integration Into Clinical Practice” from 10:00 - 11:00 am at NOMCC
Science and Technology Hall #1043
About the 4Kscore Test
The 4Kscore is the only blood test that accurately identifies risk for
aggressive prostate cancer. The 4Kscore measures the blood levels of
four different prostate-derived kallikrein proteins: Total PSA, Free
PSA, Intact PSA and Human Kallikrein-2 (hK2). These biomarkers are
combined with a patient's age, Digital Rectal Exam (DRE) status (nodule
/ no nodule), and prior negative biopsy status (yes / no) using a
proprietary algorithm to calculate the risk (probability) of finding a
Gleason Score 7 or higher prostate cancer. The four kallikrein panel of
biomarkers utilized in the 4Kscore Test is based on over a decade of
research conducted by scientists at Memorial Sloan-Kettering Cancer
Center and leading European institutions. The 4Kscore Test provides
individualized risk for the presence of aggressive prostate cancer and
adds new information to the shared decision making discussion between a
Urologist and patient.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies. For more information,
visit http://www.opko.com .
SAFE HARBOR STATEMENT
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding expected benefits of the
4Kscore, whether the 4Kscore will accurately identify men more likely to
develop distant prostate cancer metastases, whether the 4Kscore will improve
long-term prediction of distant prostate cancer metastasis, the power of
the 4Kscore to provide valuable information to accurately identify
aggressive prostate cancer, including in higher risk populations, and
guide clinical decision making, whether it will accurately
predict high-grade cancers, whether it will reduce unnecessary biopsies
by at least 25%, whether OPKO will successfully commercialize the
4Kscore, and the market for and expected sales of 4Kscore, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products, financial
condition, strategies or prospects. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors include
those described in our filings with the Securities and Exchange
Commission, as well as the risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments. In addition, forward-looking
statements may also be adversely affected by general market factors,
competitive product development, product availability, federal and state
regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150518005973/en/
OPKO Health, Inc.
David Okrongly, 305-575-4133
Source: OPKO Health, Inc.
Released May 18, 2015
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page